Page last updated: 2024-11-05

pyrene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pyrene is a polycyclic aromatic hydrocarbon consisting of four fused benzene rings. It is a white solid that is poorly soluble in water but soluble in organic solvents. Pyrene is a highly fluorescent molecule that is used in a variety of applications, including organic light-emitting diodes (OLEDs), chemical sensors, and biological imaging. The molecule is also found in the environment, where it is produced by the incomplete combustion of organic materials. Pyrene's toxicity is a concern due to its potential for DNA damage and other adverse health effects. It is a common contaminant of water and soil. Its synthesis involves a variety of methods, including the pyrolysis of coal and the synthesis of specific precursors such as acenaphthene or phenanthrene. It is a model system for understanding the electronic structure and reactivity of polycyclic aromatic hydrocarbons.'

pyrene: structure in Merck Index, 9th ed, #7746 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pyrene : An ortho- and peri-fused polycyclic arene consisting of four fused benzene rings, resulting in a flat aromatic system. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID31423
CHEMBL ID279564
CHEBI ID39106
MeSH IDM0097704

Synonyms (87)

Synonym
BIDD:ER0347
beta-pyrene
pyrene[def]phenanthrene
AB-131/40897138
nsc66449
nsc-66449
nsc17534
benzo[def]phenanthrene
nsc-17534
.beta.-pyrene
pyrene
wln: l666 b6 2ab pj
pyren
129-00-0
inchi=1/c16h10/c1-3-11-7-9-13-5-2-6-14-10-8-12(4-1)15(11)16(13)14/h1-10
NCGC00090910-01
nsc 17534
pyren [german]
ai3-23977
coal tar pitch volatiles: pyrene
benzo(def)phenanthrene
hsdb 4023
einecs 204-927-3
ccris 1256
pyrene, sublimed grade, 99%
pyrene, analytical standard
pyrene, 98%
pyrene, certified reference material, 1000 mug/ml in methanol
pyrene, crystalline, 95%
CHEBI:39106 ,
NCGC00090910-02
pyrene, puriss. p.a., for fluorescence, >=99.0% (gc)
AKOS000269680
CHEMBL279564 ,
pyrene-13c6
bdbm50214608
P1104
A805889
NCGC00090910-04
NCGC00090910-03
dtxcid804289
tox21_400063
dtxsid3024289 ,
cas-129-00-0
FT-0674169
9e0t7wfw93 ,
ec 204-927-3
unii-9e0t7wfw93
FT-0622695
EPITOPE ID:119715
pyrene [mi]
pyrene [iarc]
pyrene [hsdb]
1228182-40-8
Q-201641
coal tar pitch volatiles:pyrene
CS-B1735
P2072
mfcd00004136
pyrene, bcr(r) certified reference material
pyrene, purum, for fluorescence, >=97.0% (gc)
pyrene, certified reference material, tracecert(r)
pireno
pyrene 10 microg/ml in acetonitrile
pyrene 10 microg/ml in cyclohexane
pyrene 100 microg/ml in acetonitrile
pyrene; benzo[def]phenanthrene; nsc 17534; nsc 66449
{benzo[def]phenanthrene}
pyrene (acd/name 4.0)
pyren(german)
8p0 ,
1346601-04-4
pyrene sublimed grade
Q415723
pyrene, powder
pyrene (purified by sublimation)
AS-13613
HMS3749I11
STL570454
EN300-174930
41496-25-7
beta-pyrine
pyrene (iarc)
benzo (d,e,f) phenanthrene
benzo(d,e,f)phenanthrene
Z57901968
HY-103609

Research Excerpts

Overview

Pyrene (PYR) is a rigid, carcinogenic, unreactive, and nonelectrooxidizable compound. Pyrene is an important non-carcinogenic PAH because its metabolites are frequently used as biomarkers to assess human PAH exposure.

ExcerptReferenceRelevance
"Pyrene acts as a sensitive and selective sensor for the detection of amines in environmental samples."( Pyrene Interaction with Selected Amines in Aqueous Sodium Dodecyl Sulphate (SDS).
Idrees, M; Salam, A, 2021
)
2.79
"Pyrene (PYR) is a rigid, carcinogenic, unreactive, and nonelectrooxidizable compound. "( Electrochemical conversion of unreactive pyrene to highly redox-active 1,2-quinone derivatives on a carbon nanotube-modified gold electrode surface and its selective hydrogen peroxide sensing.
Barathi, P; Kumar, AS, 2013
)
2.1
"Pyrene (PYR) is an important non-carcinogenic PAH because its metabolites are frequently used as biomarkers to assess human PAH exposure."( Polycyclic aromatic hydrocarbons in food--efflux of the conjugated biomarker 1-hydroxypyrene is mediated by Breast Cancer Resistance Protein (ABCG2) in human intestinal Caco-2 cells.
Hessel, S; Lampen, A; Seidel, A, 2013
)
1.33
"Pyrene (PY) is a polycyclic aromatic hydrocarbon (PAH) that is often used as a biomarker for human and wildlife exposure to PAHs. "( Characterization and tissue distribution of conjugated metabolites of pyrene in the rat.
Darwish, WS; Ikenaka, Y; Ishizuka, M; Mizukawa, H; Nakayama, SM; Saengtienchai, A, 2015
)
2.09
"Pyrene acts as a probe to ascertain the critical micellar concentration (cmc) by using fluorescence spectroscopy."( Methotrexate-Loaded Four-Arm Star Amphiphilic Block Copolymer Elicits CD8+ T Cell Response against a Highly Aggressive and Metastatic Experimental Lymphoma.
Gupta, U; Hira, SK; Manna, PP; Misra, N; Mitra, K; Ramesh, K; Ray, B, 2015
)
1.14
"Pyrene is a common organic luminescent material. "( A pyrene-bridged macrocage showing no excimer fluorescence.
Inagaki, Y; Setaka, W; Shionari, H; Yamaguchi, K, 2015
)
2.58
"The pyrene motif is a common DNA intercalator and allowed us to test the influence of the radionuclide distance on damages of the DNA helix."( Direct and Auger Electron-Induced, Single- and Double-Strand Breaks on Plasmid DNA Caused by 99mTc-Labeled Pyrene Derivatives and the Effect of Bonding Distance.
Caballero, J; Freudenberg, R; Kotzerke, J; Mamat, C; Navarro-Retamal, C; Pietzsch, HJ; Reissig, F; Steinbach, J; Wunderlich, G, 2016
)
1.13
"Pyrene is a highly sensitive fluorophore that reports on spatial proximity between desired sites by displaying unique spectral features."( Pyrene fluorescence analysis offers new insights into the conformation of the lipoprotein-binding domain of human apolipoprotein E.
Khumsupan, P; Narayanaswami, V; Patel, AB, 2010
)
2.52
"Pyrene is a fluorescent probe that can be attached covalently to protein side chains, such as sulfhydryl groups."( Pyrene: a probe to study protein conformation and conformational changes.
Bains, G; Narayanaswami, V; Patel, AB, 2011
)
2.53
"Pyrene is a spatially sensitive probe that displays an ensemble of monomeric fluorescence emission peaks (375-405 nm) and an additional band (called excimer) at ~460 nm when two fluorophores are spatially proximal. "( The extent of pyrene excimer fluorescence emission is a reflector of distance and flexibility: analysis of the segment linking the LDL receptor-binding and tetramerization domains of apolipoprotein E3.
Bains, GK; Kim, SH; Narayanaswami, V; Sorin, EJ, 2012
)
2.18
"Pyrene is a regulated pollutant at sites contaminated with polycyclic aromatic hydrocarbons (PAH). "( Products from the incomplete metabolism of pyrene by polycyclic aromatic hydrocarbon-degrading bacteria.
Aitken, MD; Kazunga, C, 2000
)
2.01

Effects

Pyrene acylhydrazone has sensitive concentration- and polarity-dependent fluorescence spectra. The sensitivity on polarity is at most 26 times higher than the old vibrationally resolved patterns. Pyrene has the property of forming excimer that has a large Stokes shift and long fluorescence lifetime.

ExcerptReferenceRelevance
"The pyrene acylhydrazone has sensitive concentration- and polarity-dependent fluorescence spectra (the sensitivity on polarity is at most 26 times higher than the old vibrationally resolved patterns), and the sensitivity well remains when it is copolymerized in a polymer."( A Sensitive Concentration- and Polarity-Dependent Pyrene-Derived Vibrationally Resolved Fluorescence Probe for The Polymer Interdiffusion Study.
Mo, R; Sheng, X; Zhang, F; Zhang, X, 2023
)
1.64
"Pyrene has the property of forming excimer that has a large Stokes shift and long fluorescence lifetime."( Pyrene excimer nucleic acid probes for biomolecule signaling.
Wang, C; Wu, C; Yan, L; Yang, CJ, 2009
)
2.52
"The pyrene label has been shown to serve as a useful fluorescence reporter group for conformational and interaction events of the N-terminal regulatory domain of TnC with only minimal fluorescence changes associated with C-terminal domain."( Differential pH effect on calcium-induced conformational changes of cardiac troponin C complexed with cardiac and fast skeletal isoforms of troponin I and troponin T.
Chang, JC; Liou, YM, 2004
)
0.8

Actions

Pyrene may enhance fragmentation and stabilize the cleaved fragments by intramolecular or intermolecular weak interactions including hydrogen bonding. Pyrene was found to cause a dose dependant decrease in lactate and the concentrations of the saturated fatty acids.

ExcerptReferenceRelevance
"Amidopyrene moiety might enhance fragmentation and stabilize the cleaved fragments by intramolecular or intermolecular weak interactions including hydrogen bonding."( 6-Amidopyrene as a label-assisted laser desorption/ionization (LA-LDI) enhancing tag: development of photoaffinity pyrene derivative.
Hu, Y; Kigoshi, H; Kita, M; Yoneda, K, 2015
)
1.33
"Pyrene was found to cause a dose dependant decrease in lactate and the concentrations of the saturated fatty acids tetradecanoic, hexadecanoic and octadecanoic acid and an increase in production of the amino acids alanine, leucine, valine, isoleucine, lysine, tyrosine and methionine."( A metabolomics based approach to assessing the toxicity of the polyaromatic hydrocarbon pyrene to the earthworm Lumbricus rubellus.
Griffin, JL; Jones, OA; Spurgeon, DJ; Svendsen, C, 2008
)
1.29

Treatment

Pyrene-treated embryos showed dose-dependent heart abnormalities, such as pericardial edema and cardiac looping defects. Treatment with pyrene did not markedly affect the Na(+),K(+)-ATPase activity of sciatic nerve.

ExcerptReferenceRelevance
"Pyrene-treated embryos showed dose-dependent heart abnormalities, such as pericardial edema and cardiac looping defects."( Low-level pyrene exposure causes cardiac toxicity in zebrafish (Danio rerio) embryos.
Chen, R; Chen, Y; Huang, L; Wang, C; Zhang, Y; Zuo, Z, 2012
)
1.5
"In pyrene-treated cells, SOD induction (P<0."( Polycyclic aromatic hydrocarbon coated onto Fe(2)O(3) particles: assessment of cellular membrane damage and antioxidant system disruption in human epithelial lung cells (L132) in culture.
Fontaine, M; Garçon, G; Garry, S; Hannothiaux, MH; Martin, A; Shirali, P; Zerimech, F, 2000
)
0.82
"Treatment with pyrene did not markedly affect the Na(+),K(+)-ATPase activity of sciatic nerve."( Alterations of motor nerve functions in animals exposed to motorcycle exhaust.
Chuu, JJ; Lin-Shiau, SY; Liu, SH; Wang, JH, 2002
)
0.65

Toxicity

Pyrene is one of the major polycyclic aromatic hydrocarbons formed during heat treatment of meat and in car exhausts. Few studies have investigated pyrene-induced adverse effects on human cell lines. The toxic effects of pyrene on the microalgae probably led to the release of organic matter.

ExcerptReferenceRelevance
" Although the ozonation products of pyrene were not toxic under the conditions of this study, phenanthrene products were more hepatotoxic than was phenanthrene itself."( Toxicity of polycyclic aromatic hydrocarbons. I. Effect of phenanthrene, pyrene, and their ozonized products on blood chemistry in rats.
Church, DF; Flory, W; Giamalva, D; Pryor, WA; Ruhr, LP; Yoshikawa, T, 1985
)
0.78
" The rates of photomodification of the three PAHs were rapid enough for the photooxidized compounds to contribute to toxicity, and the photomodified PAHs were more toxic than the parent compounds."( Photoinduced toxicity of three polycyclic aromatic hydrocarbons (fluoranthene, pyrene, and naphthalene) to the duckweed Lemna gibba L. G-3.
Dixon, DG; Greenberg, BM; Huang, XD; McConkey, BJ; Ren, L, 1994
)
0.52
"The authors previously demonstrated that simulated solar radiation (SSR), with a fluence rate of only 40 mumol m-2 sec-1, increased polycyclic aromatic hydrocarbon (PAH) toxicity to the duckweed Lemna gibba and that PAHs photomodified in SSR (generally oxygenation of the ring system) are more toxic than the parent compounds (Huang et al."( Increased polycyclic aromatic hydrocarbon toxicity following their photomodification in natural sunlight: impacts on the duckweed Lemna gibba L. G-3.
Dixon, DG; Greenberg, BM; Huang, XD, 1995
)
0.29
" This study has shown that the three polycyclic aromatic hydrocarbons tested are not acutely toxic to the prokaryotic biosensors tested, although acute toxicity has been shown in other bioassays."( Feasibility of using prokaryote biosensors to assess acute toxicity of polycyclic aromatic hydrocarbons.
Macleod, CJ; Paton, GI; Reid, BJ; Semple, KT; Weitz, HJ, 1998
)
0.3
" Toxic effects were measured as reductions in survival and reproductive output after 3 weeks of exposure."( Studies on the effect of soil aging on the toxicity of pyrene and phenanthrene to a soil-dwelling springtail.
Jensen, J; Krogh, PH; Stenersen, J; Sverdrup, LE, 2002
)
0.56
" Both the toxic unit concept and the isobologram method indicated that an additive approach would be the most useful when assessing the risk of these two compounds."( Joint toxicity of linear alkylbenzene sulfonates and pyrene on Folsomia fimetaria.
Jensen, J; Sverdrup, LE, 2002
)
0.56
" The lowest observable adverse effect concentration (LOAEC) was 10 mg/kg for phenanthrene when tested with green onion, and 50 mg/kg for pyrene when tested with wheat."( Phytotoxicity assessment of phenanthrene, pyrene and their mixtures by a soil-based seedling emergence test.
Gong, P; Song, YF; Sun, TH; Zhou, QX, 2005
)
0.8
" The fulvic acid gave no toxic response, but the humic acid showed significant toxicity."( Humic acid toxicity in biologically treated soil contaminated with polycyclic aromatic hydrocarbons and pentachlorophenol.
McLean, JE; Nieman, JK; Sims, RC; Sorensen, DL, 2005
)
0.33
" The toxic effects of pyrene on the microalgae probably led to the release of organic matter."( Phototoxicity of pyrene affects benthic algae and bacteria from the Arctic.
Dahllöf, I; Petersen, DG; Reichenberg, F, 2008
)
1
" Main findings in the SSB that assessed mainly the toxicity of PY and its metabolites were: increased levels of bile PY metabolites in good agreement with the profile of lipid peroxidation levels (LPO) in exposed fish relating PY exposure and oxidative damage; increased levels of PY-type compounds in the brain indicating their ability to cross the blood-brain barrier; increased levels of these substances in liver and muscle which are edible tissues for humans thus raising concern on potential adverse effects on consumers of fish from PY contaminated areas; a significant inhibition of glutathione S-transferase activity suggesting its involvement in PY detoxication as toxicant scavenger; finally, an almost complete impairment of the swimming velocity at all the PY concentrations linking sub-individual to higher population level effects."( Challenges in assessing the toxic effects of polycyclic aromatic hydrocarbons to marine organisms: a case study on the acute toxicity of pyrene to the European seabass (Dicentrarchus labrax L.).
Almeida, JR; Gravato, C; Guilhermino, L, 2012
)
0.58
"The short-term (96 h) toxic effects of two polycyclic aromatic hydrocarbons (PAHs), naphthalene (NAP) and pyrene (PYR), on the common prawn (Palaemon serratus) were investigated in laboratory bioassays, including a fitness related assay based on the post-exposure swimming velocity."( Short-term toxic effects of naphthalene and pyrene on the common prawn (Palaemon serratus) assessed by a multi-parameter laboratorial approach: mechanisms of toxicity and impairment of individual fitness.
Guilhermino, L; Luís, LG, 2012
)
0.85
" Furthermore, an analysis of the toxic effects at several trophic levels is essential for a more comprehensive understanding of the damage caused by highly contaminated soil."( Biotoxicity assessment of pyrene in soil using a battery of biological assays.
Cheema, SA; Chen, Y; Jabbar, A; Khan, MI; Park, J; Sahi, ST; Shen, C; Tang, X, 2012
)
0.68
" Interestingly, the overall toxic effects of Pyr and MePyr considerably overlapped those induced following dioxin exposure."( Transcriptional responses and embryotoxic effects induced by pyrene and methylpyrene in Japanese medaka (Oryzias latipes) early life stages exposed to spiked sediments.
Barjhoux, I; Baudrimont, M; Budzinski, H; Cachot, J; Gonzalez, P; Landi, L; Le Menach, K; Morin, B, 2014
)
0.64
" Photo-enhanced toxicity from co-exposure to ultraviolet (UV) radiation and PAHs enhanced the toxicity and exhibited toxic effects at PAH concentrations orders of magnitude below effects observed in the absence of UV."( Acute photo-induced toxicity and toxicokinetics of single compounds and mixtures of polycyclic aromatic hydrocarbons in zebrafish.
Oris, JT; Willis, AM, 2014
)
0.4
" Therefore, we aimed to determine the toxic effects of PAHs on earthworms."( Determination of biomarkers for polycyclic aromatic hydrocarbons (PAHs) toxicity to earthworm (Eisenia fetida).
Cho, K; Jeon, HJ; Lee, SE; Mo, HH; Nam, TH; Ok, YS, 2015
)
0.42
" Here, we evaluated the adverse effects of pyrene, a common PAH, on the liver."( Pyrene is a Novel Constitutive Androstane Receptor (CAR) Activator and Causes Hepatotoxicity by CAR.
Englert, NA; He, X; Lyv, JX; Shi, Z; Zhang, SY; Zhang, XJ, 2015
)
2.12
" The ∑PAH16 in all sediments were significantly lower than probable effect concentrations (PEC), while ∑PAH16 at nine sites of the Daliao River system were between threshold effect concentrations (TEC) and PEC, suggesting that adverse effects were possible at the nine sites."( Spatial distribution and potential toxicity of polycyclic aromatic hydrocarbons in sediments from Liaohe River Basin, China.
Guo, C; He, Y; Meng, W; Xu, J; Zhang, Y, 2016
)
0.43
" Cytotoxicity as assessed by the classic 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and neutral red assays showed a mild toxic effect in response to single or multiple dose exposure for up to 72 h, except for multiple dose exposure to BaA and 7-ClBaA (1 μM/d for 4 d) and single exposure to 10 μM BaA."( Integration of cellular and molecular endpoints to assess the toxicity of polycyclic aromatic hydrocarbons in HepG2 cell line.
Cardoso, AS; Jordao, L; Jose, S; M Antunes, AM; Morgado, PI; Wanke, R, 2017
)
0.46
"Polycyclic aromatic hydrocarbons (PAHs) are a group of persistent organic pollutants primarily formed from the incomplete combustion of carbonaceous materials, and have adverse effects on human health."( Identification of hepatotoxicity and renal dysfunction of pyrene in adult male rats.
Shi, Z; Wang, XX; Wu, G; Zhang, SY; Zhang, Y; Zhao, LY; Zhu, J, 2018
)
0.73
"Pyrene is one of the major polycyclic aromatic hydrocarbons formed during heat treatment of meat and in car exhausts; however, few studies have investigated pyrene-induced adverse effects on human cell lines."( Effects of Pyrene on Human Liver HepG2 Cells: Cytotoxicity, Oxidative Stress, and Transcriptomic Changes in Xenobiotic Metabolizing Enzymes and Inflammatory Markers with Protection Trial Using Lycopene.
El-Ghareeb, WR; Elhelaly, AE; Huang, XC; Khedr, MHE; Li, X; Ma, JK; Saad Eldin, WF, 2019
)
2.35
"Polycyclic aromatic hydrocarbons are persistent organic pollutants causing serious environmental problems, being toxic to plants and difficult to remediate."( Diminishing toxicity of pyrene on photosynthetic performance of soybean using
Jain, L; Jajoo, A, 2023
)
1.22

Pharmacokinetics

The method described herein had been successfully applied for the pharmacokinetic studies in female Wistar rats after administration of 10mg equivalent pyrene/kg dose of solution of pyrene. The analysis of blood concentration data using a one-compartment pharmacokinetics model revealed that the uptake and elimination kinetic parameters were dose dependent.

ExcerptReferenceRelevance
" The analysis of blood concentration data using a one-compartment pharmacokinetic model revealed that the uptake and elimination kinetic parameters were dose dependent, for both total radioactivity (pyrene plus metabolites) and for pyrene per se, over the range of exposures used in this study."( Pharmacokinetics of inhaled pyrene in rats.
Abedini, S; Burnett, R; Endrenyi, L; Law, FC; Withey, JR, 1994
)
0.77
" A clearance study conducted for the grain showed the half-life of clearance was approximately 20 days for all compounds studied."( Controlled exposure chamber study of uptake and clearance of airborne polycyclic aromatic hydrocarbons by wheat grain.
Cahill, TM; Kado, NY; Kobayashi, R; Maddalena, RL; Okamoto, RA, 2007
)
0.34
" The method described herein had been successfully applied for the pharmacokinetic studies in female Wistar rats after administration of 10mg equivalent pyrene/kg dose of solution of pyrene and 1mg equivalent pyrene/kg dose of pyrene-loaded nanoparticle."( An improved HPLC method with fluorescence detection for the determination of pyrene in rat plasma and its pharmacokinetics.
Wan, J; Xu, H; Yang, X; Zhao, X, 2008
)
0.77
"During the pharmacokinetic processes of nanoparticles, encapsulated drugs and non-encapsulated (free and protein-bound) drugs are the drug forms existing in plasma."( A novel method for the separation and determination of non-encapsulated pyrene in plasma and its application in pharmacokinetic studies of pyrene-loaded MPEG-PLA based nanoparticles.
Mou, D; Wan, J; Xu, H; Yang, X; Zhao, X, 2009
)
0.59

Compound-Compound Interactions

The interactions of pyrene (Pyr) with bovine serum albumin (BSA) in binary and ternary systems were investigated. Adult survival of the springtail Protaphorura armata exposed to pyrene was investigated in combination with cold and drought stress.

ExcerptReferenceRelevance
"Adult survival of the springtail Protaphorura armata exposed to pyrene, a common soil pollutant, was investigated in combination with cold and drought stress, in three separate experiments."( Cold and drought stress in combination with pyrene exposure: studies with Protaphorura armata (Collembola: Onychiuridae).
Holmstrup, M; Sjursen, H, 2004
)
0.82
"The interactions of pyrene (Pyr) and/or 1-hydroxypyrene (1-OHPyr) with bovine serum albumin (BSA) in binary and ternary systems were investigated using the excitation-emission matrix (EEM)-parallel factor analysis (PARAFAC) method combined with fluorescence quenching analysis and the molecular docking method."( Interactions of pyrene and/or 1-hydroxypyrene with bovine serum albumin based on EEM-PARAFAC combined with molecular docking.
Chen, L; Liu, D; Zhang, J; Zhang, Y; Zhu, Y, 2018
)
1.15

Bioavailability

The addition of PGPB efficiently decreased bioaccessible fractions of pyrene and increased the bioavailability of Ni in both rhizospheric and non-rhizosphere soil. The interactions among the consortia of plant root exudates, microorganisms, and amended compost in rhizosphere soils could facilitate bioavailability and subsequently enhance its dissipation.

ExcerptReferenceRelevance
" A significant increase in the bioavailability of pyrene after treatment with other PAHs was observed."( Effect of polycyclic aromatic hydrocarbons on the elimination kinetics of pyrene and the urinary excretion profile of 1-hydroxypyrene in the rat.
Lipniak-Gawlik, M, 1998
)
0.78
" Bioavailability of sediment-sorbed PAHs declined with contact time between sediment and animals."( Accumulation kinetics of polycyclic aromatic hydrocarbons adsorbed to sediment by the mollusk Corbicula fluminea.
Djomo, JE; Ferrier, V; Garrigues, P; Narbonne, JF; Ribera, D, 1999
)
0.3
"The binding and bioavailability of pyrene was studied in the laboratory in two humic fresh waters and in a reference water without dissolved organic material (DOM), measured as dissolved organic carbon (DOC)."( Effects of dissolved organic material on binding and toxicokinetics of pyrene in the waterflea Daphnia magna.
Kukkonen, JV; Nikkilä, A, 2001
)
0.82
"To better understand complex bioavailability issues, pyrene degradation was examined in aqueous and soil slurry solutions using pure Mycobacterium sp."( Pyrene biodegradatin in aqueous solutions and soil slurries by Mycobacterium PYR-1 and enriched consortium.
Cutright, T; Ju, LK; Ramirez, N, 2001
)
2
" The effects of dissolved organic matter (DOM) on the bioavailability of atrazine, pyrene and benzo[a]pyrene (B[a]P) was evaluated."( Bioavailability of atrazine, pyrene and benzo[a]pyrene in European river waters.
Akkanen, J; Haitzer, M; Kukkonen, JV; Penttinen, S, 2001
)
0.83
"Colloidal organic particles constitute the dominant portion of particulate organic matter in surface seawater, but their influence on the phase speciation and bioavailability of hydrophobic organic compounds (HOCs) is sparsely evaluated."( Dynamic colloid--water partitioning of pyrene through a coastal Baltic spring bloom.
Bucheli, TD; Gustafsson, O; Nilsson, N, 2001
)
0.58
" Mixed-surfactant solutions may improve the performance of the surfactant-enhanced remediation (SER) of soils by increasing the bioavailability and biodegradation of non-aqueous-phase organic pollutants and reducing the level of surfactant pollution and remediation expenses."( Water solubility enhancements of pyrene by single and mixed surfactant solutions.
Chiou, CT; Zhu, LZ, 2001
)
0.59
" Many studies have shown a negative correlation between aging and the biodegradation of polycyclic aromatic hydrocarbons (PAHs), indicating a reduction in the bioavailability of PAHs to micro-organisms with time."( Studies on the effect of soil aging on the toxicity of pyrene and phenanthrene to a soil-dwelling springtail.
Jensen, J; Krogh, PH; Stenersen, J; Sverdrup, LE, 2002
)
0.56
" If LAS was able to increase the bioavailability of pyrene to springtails, it was expected that the combined effect of the two substances would exceed the effect found for each of the compounds tested separately."( Joint toxicity of linear alkylbenzene sulfonates and pyrene on Folsomia fimetaria.
Jensen, J; Sverdrup, LE, 2002
)
0.81
" Therefore, PAH bioavailability in the aged soils can be underestimated when the microbial activity is determined only from the stagnant solution."( Biodegradability of aged pyrene and phenanthrene in a natural soil.
Cutright, TJ; Hwang, S, 2002
)
0.62
" Results showed that there was a decline in bioavailability with time and that this was a 3 stage process."( Pyrene bioavailability; effect of sediment-chemical contact time on routes of uptake in an oligochaete worm.
Comber, SD; Conrad, AU; Simkiss, K, 2002
)
1.76
"Polycyclic aromatic hydrocarbon (PAHs)-degrading bacteria may enhance the bioavailability of PAHs by excreting biosurfactants, by production of extracellular polymeric substances, or by forming biofilms."( Evaluation of bacterial strategies to promote the bioavailability of polycyclic aromatic hydrocarbons.
Johnsen, AR; Karlson, U, 2004
)
0.32
"Various techniques exist for polycyclic aromatic hydrocarbon (PAH) determination in environmental samples, but an adequate risk assessment of PAHs should include aspects such as bioavailability of the contaminant and biotransformation capacity of the species under investigation."( Pyrene biotransformation and kinetics in the hepatopancreas of the isopod Porcellio scaber.
Ariese, F; Gestel, CA; Hattum Bv, Bv; Straalen, NM; Stroomberg, GJ; Velthorst, NH, 2004
)
1.77
" These findings suggested that intestinal metabolism might play a key role in intestinal barrier permeability and thus in the bioavailability of tested micropollutants."( Intestinal metabolism of PAH: in vitro demonstration and study of its impact on PAH transfer through the intestinal epithelium.
Cavret, S; Feidt, C, 2005
)
0.33
" Their bioavailability is limited by a low aqueous solubility, which causes specific adaptations in degrading bacteria."( Degradation of anthracene and pyrene supplied by microcrystals and non-aqueous-phase liquids.
Kaestner, M; Mutnuri, S; Vasudevan, N, 2005
)
0.62
"In bioavailability studies, the biota sediment accumulation factor (BSAF) is invoked to describe the thermodynamic partitioning of a hydrophobic organic contaminant (HOC) between the organism lipid and the organic carbon fraction of the sedimentary matrix and accounts for differences in bioavailability among sediments."( The contrasting roles of sedimentary plant-derived carbon and black carbon on sediment-spiked hydrophobic organic contaminant bioavailability to Diporeia species and Lumbriculus variegatus.
Gossiaux, DC; Gunnarsson, J; Kukkonen, JV; Landrum, PF; Mitra, S; Weston, D, 2005
)
0.33
"It is well known that the limited aqueous solubilities of polycyclic aromatic hydrocarbons (PAH) often reduce their bioavailability to bacterial populations."( Influence of hydroxypropyl-beta-cyclodextrin (HPCD) on the bioavailability and biodegradation of pyrene.
Brusseau, ML; Maier, RM; Wang, JM, 2005
)
0.55
" The observed low bioavailability of PAHs probably inhibited PAH phytoremediation, as diffusion-limited mass transfer would limit the release of PAHs to the aqueous phase."( Physicochemical characterization of coke-plant soil for the assessment of polycyclic aromatic hydrocarbon availability and the feasibility of phytoremediation.
Ahn, S; Luthy, RG; Werner, D, 2005
)
0.33
" The displacement data indicated that the cocontaminant can have potential effects on the fate and bioavailability of anthropogenic organic pollutants sorbed in soils and sediments, thus affecting their exposure risks."( Sorption and displacement of pyrene in soils and sediments.
Sato, T; Wang, X; Xing, B, 2005
)
0.62
"The impacts of microbially mediated redox conditions on the bioavailability of persistent polycyclic aromatic hydrocarbons (PAHs) in soils and sediments have received little study, despite the fact that most water-saturated soils and sediments spend a significant portion of the time under reduced conditions."( Effects of microbially mediated redox conditions on PAH-soil interactions.
Kim, HS; Pfaender, FK, 2005
)
0.33
"Effect of aging on bioavailability and extractability of persistent organic pollutants has recently been paid much attention in environmental studies."( [Aging of spiked pyrene in two paddy soils and their particle-size fractions after soil incubation and changes in extractability and bio-availability to earthworm].
Li, JH; Pan, GX, 2005
)
0.67
" Overall, a single HPCD-extraction technique proved accurate and reproducible for the estimation of PAH bioavailability from soil."( Further validation of the HPCD-technique for the evaluation of PAH microbial availability in soil.
Clasper, PJ; Doick, KJ; Semple, KT; Urmann, K, 2006
)
0.33
" In addition, high adsorption capacity of PAHs by carbon nanotubes may add to their high environmental risks once released to the environment, and result in potential alteration of PAHs fate and bioavailability in the environment."( Adsorption of polycyclic aromatic hydrocarbons by carbon nanomaterials.
Xing, B; Yang, K; Zhu, L, 2006
)
0.33
"Changes in bioavailability of pyrene in three uncontaminated soils were examined under aerobic and anaerobic conditions."( Microbial bioavailability of pyrene in three laboratory-contaminated soils under aerobic and anaerobic conditions.
Christman, RF; Pfaender, FK; Pravecek, TL, 2006
)
0.91
" Hence, SFS is a potential means to simplify the present non-exhaustive hydroxypropyl-beta-cyclodextrin (HPCD)-based extraction technique for the evaluation of PAH bioavailability in soil."( Rapid quantification of polycyclic aromatic hydrocarbons in hydroxypropyl-beta-cyclodextrin (HPCD) soil extracts by synchronous fluorescence spectroscopy (SFS).
Broderick, J; Hua, G; Killham, K; Semple, KT; Singleton, I, 2007
)
0.34
" DNA, RNA or proteins, thus reducing pyrene bioavailability to arm-cropping predators."( Effects of sediment organic matter quality on bioaccumulation, degradation, and distribution of pyrene in two macrofaunal species and their surrounding sediment.
Granberg, ME; Selck, H, 2007
)
0.83
"Recent reports suggest that Mycobacterium is better adapted to soils containing poorly bioavailable polycyclic aromatic hydrocarbons (PAHs) compared to Sphingomonas."( Differential responses of eubacterial, Mycobacterium, and Sphingomonas communities in polycyclic aromatic hydrocarbon (PAH)-contaminated soil to artificially induced changes in PAH profile.
Bastiaens, L; Ortega-Calvo, JJ; Spoden, A; Springael, D; Uyttebroek, M; Wattiau, P; Wouters, K,
)
0.13
"In order to develop a new method to study the desorption and bioavailability of hydrophobic organic chemicals (HOCs) in soils, a method using semi-permeable membrane device (SPMD) to study desorption of HOCs in soils has been set up, and assisted desorption of polycyclic aromatic hydrocarbons (PAHs), phenanthrene(PHE), pyrene(PYE), and benzo[a] pyrene (B[a]PYE) in three different kinds of soils was studied using SPMD."( [Desorption of polycyclic aromatic hydrocarbons in soils assisted by SPMD].
Huo, C; Sun, HW; Wang, CP, 2007
)
0.51
"Humic substances may influence the bioavailability of polycyclic aromatic hydrocarbons (PAHs) in aquatic environment."( Humic substances modify accumulation but not biotransformation of pyrene in salmon yolk-sac fry.
Honkanen, JO; Kukkonen, JV; Wiegand, C, 2008
)
0.58
"Desorption of pyrene from three different soils was studied using a semipermeable membrane device (SPMD)-assisted method to develop a new approach to predict bioavailability of hydrophobic organic compounds (HOCs) in soils."( Semipermeable membrane device-assisted desorption of pyrene from soils and its relationship to bioavailability.
Huo, C; Sun, H; Wang, C; Zhou, Z, 2008
)
0.96
" SDBS could affect the bioavailability of pyrene in aquatic systems."( Effects of sodium dodecylbenzenesulfonate on uptake of pyrene by fish gills.
Liu, G; Liu, X; Tao, S; Wang, W; Wu, W; Xie, J; Xie, Y; Xu, W; Xue, B; Zhang, N; Zhu, Y, 2008
)
0.86
" The effects of organic matter (OM) and soil aging on the bioavailability of pyrene in soil were investigated by generation of reproductive effect concentrations (EC50) for the euedaphic springtail, Folsomia candida, under various test conditions."( Solid-phase microextraction (SPME) as a tool to predict the bioavailability and toxicity of pyrene to the springtail, Folsomia candida, under various soil conditions.
Andersen, O; Jensen, J; Krogh, PH; Mortensen, M; Styrishave, B, 2008
)
0.79
" While the positive effect of Tween 80 on PYR removal could probably due to its capacities to enhance PYR bioavailability in soil."( Effects of pig manure compost and nonionic-surfactant Tween 80 on phenanthrene and pyrene removal from soil vegetated with Agropyron elongatum.
Cheng, KY; Lai, KM; Wong, JW, 2008
)
0.57
" It was concluded that adsorption of PAH onto these particles could decrease their bioavailability and so their abilities to affect cell cytokine production."( Effect of polycyclic aromatic hydrocarbons and carbon black particles on pro-inflammatory cytokine secretion: impact of PAH coating onto particles.
Bennasroune, A; Falla, J; Foucaud, L; Goulaouic, S; Laval-Gilly, P, 2008
)
0.35
" CTAC could affect the bioavailability ofpyrene in aquatic systems."( Effects of cetyltrimethylammonium chloride on uptake of pyrene by fish gills.
Liu, G; Liu, X; Tao, S; Wang, W; Wu, W; Xie, J; Xie, Y; Xu, W; Yu, X; Zhang, N; Zhu, Y, 2009
)
0.87
"This study presents the bioavailability of four spiked compounds to Lumbriculus variegatus, in sediment samples from three river basins in Europe: the Elbe, the Llobregat, and the Scheldt."( Predicting the bioavailability of sediment-associated spiked compounds by using the polyoxymethylene passive sampling and tenax extraction methods in sediments from three river basins in Europe.
Akkanen, J; Kukkonen, JV; Leppänen, MT; Sormunen, AJ; Tuikka, AI, 2010
)
0.36
"In order to develop a new method to study the mobility and bioavailability of organic contaminants in soils, a set of thermal desorption device was established."( [Comparative study on water desorption and thermal desorption of aromatic hydrocarbons in soils].
Sun, HW; Zhang, W; Zhang, Y, 2010
)
0.36
" This study supports the use of bile fluorescence in Nile tilapia by fixed wavelength fluorescence and synchronous fluorescence spectrometry with non-normalized data as a simple method for screening bioavailability of these PAHs."( Assessment of bile fluorescence patterns in a tropical fish, Nile tilapia (Oreochromis niloticus) exposed to naphthalene, phenanthrene, pyrene and chrysene using fixed wavelength fluorescence and synchronous fluorescence spectrometry.
Hemachandra, CK; Pathiratne, A; Pathiratne, KA, 2010
)
0.56
"985) and extraction results for pyrene suggested that mild HPCD extraction was a better method to predict bioavailability of pyrene in soil compared with organic solvent extraction."( Assessment of pyrene bioavailability in soil by mild hydroxypropyl-β-cyclodextrin extraction.
Cheema, SA; Chen, X; Chen, Y; Khan, MI; Malik, Z; Shen, C; Tang, X; Zhang, C, 2011
)
1.01
"The nature of bioavailability of DNA-intercalated PAHs in aqueous solution was investigated."( Nature of bioavailability of DNA-intercalated polycyclic aromatic hydrocarbons to Sphingomonas sp.
Ichikawa, H; Iimura, Y; Navarro, RR; Tatsumi, K, 2010
)
0.36
"Microbial degradation is the dominant pathway for natural attenuation of PAHs in environmental compartments such as sediments, which in turn depends on the bioavailability of PAHs."( Biodegradation of pyrene in sand, silt and clay fractions of sediment.
Chen, Y; Cui, X; Gan, J; Hunter, W; Yang, Y, 2011
)
0.7
" viminalis or the surfactant enhanced PAH degradation, primarily by a rhizosphere effect on the microbial activity in the former case and by increased bioavailability in the latter case."( Degradation of PAH in a creosote-contaminated soil. A comparison between the effects of willows (Salix viminalis), wheat straw and a nonionic surfactant.
Castillo, Mdel P; Granhall, U; Hultgren, J; Pizzul, L, 2010
)
0.36
" An existing state of the art probabilistic bioaccumulation model was improved by accounting for bioavailability and absorption efficiency limitations, due to the presence of black carbon in sediment, and was used for probabilistic modeling of variability and propagation of error."( Explaining differences between bioaccumulation measurements in laboratory and field data through use of a probabilistic modeling approach.
Drouillard, K; Eisenreich, K; Koelmans, AA; Palmqvist, A; Ruus, A; Salvito, D; Schultz, I; Selck, H; Stewart, R; van den Brink, NW; van den Heuvel-Greve, M; Weisbrod, A, 2012
)
0.38
" However, the concentration-dependent and potential effects of CMs on the decrease in HOC bioavailability are not well understood."( Influences of multiwalled carbon nanotubes and plant residue chars on bioaccumulation of polycyclic aromatic hydrocarbons by Chironomus plumosus larvae in sediment.
Shen, M; Wang, F; Xia, X; Zhang, P; Zhao, X, 2012
)
0.38
"Solid phase microextraction (SPME) coupled with gas chromatography was employed to estimate bioavailability of pyrene in soils with different properties of textures, organic matter contents (SOM) and aging periods."( Reliability of solid phase microextraction in estimating bioavailability of pyrene in soil.
Chang, HY; Hung, JM; Hwu, CS; Lai, HY; Liu, HC; Lu, CJ, 2011
)
0.81
" It was thus suggested that the interactions among the consortia of plant root exudates, microorganisms, and amended compost in rhizosphere soils could facilitate bioavailability of pyrene and subsequently enhance its dissipation."( Phytoremediation of pyrene contaminated soils amended with compost and planted with ryegrass and alfalfa.
Chang Chien, SW; Chen, SH; Chen, YT; Sunkara, SV; Wang, MC, 2012
)
0.89
" Tween 80 significantly improves the biodegradation of pyrene by increasing the bioavailability of pyrene."( Microcalorimetric investigation of the effect of non-ionic surfactant on biodegradation of pyrene by PAH-degrading bacteria Burkholderia cepacia.
Chen, K; Choi, MM; Qian, Y; Song, Y; Yao, J; Zhu, Q, 2013
)
0.86
" Overall, this study provides advanced mechanistic insights into the bioavailability of PYR and underlines a key role of the human small intestinal epithelium for the first pass metabolism of contaminants in food."( Polycyclic aromatic hydrocarbons in food--efflux of the conjugated biomarker 1-hydroxypyrene is mediated by Breast Cancer Resistance Protein (ABCG2) in human intestinal Caco-2 cells.
Hessel, S; Lampen, A; Seidel, A, 2013
)
0.61
" The enhanced PAHs degradation in FCOM-amended sediments was related to higher PAH-degrading bacteria number and bioavailability with a result of biostimulation and priming effect by labile carbon and high-value nutrition in FCOM."( Accelerated removal of pyrene and benzo[a]pyrene in freshwater sediments with amendment of cyanobacteria-derived organic matter.
Jiang, H; Li, X; Shi, Y; Yan, Z, 2014
)
0.71
" Furthermore, under the combined conditions, the degradation of PAH increased with the biosurfactant concentration, and the soil DOM added system showed slightly higher degradation than the compost DOM added system, indicating that the chemical structure and composition of DOM would also affect the bioavailability of PAHs."( Combined effects of DOM and biosurfactant enhanced biodegradation of polycylic armotic hydrocarbons (PAHs) in soil-water systems.
Chen, W; Huang, GH; Wang, L; Xiao, H; Yu, H, 2014
)
0.4
" These results may be explained by the lower sorption loss and reduced interfacial tension of mixed surfactants relative to Tween 80, which enhanced the bioavailability of PAHs in soil and the microbial degradation efficiency."( Enhancing plant-microbe associated bioremediation of phenanthrene and pyrene contaminated soil by SDBS-Tween 80 mixed surfactants.
Ni, H; Zhou, W; Zhu, L, 2014
)
0.64
" Both sterilization and aging could reduce SOM content and alter its structure, which also influenced the bioavailability of pyrene and the enzyme activity."( Biodegradation of pyrene by Phanerochaete chrysosporium and enzyme activities in soils: effect of SOM, sterilization and aging.
Liu, H; Sun, H; Wang, B; Wang, C, 2014
)
0.94
" The decline in bioavailability caused by aging on sorbed (14)C-pyrene was partially reversed by rhamnolipids, which enhanced mineralization of the aged compound, although not so efficiently like with the unaged chemical."( Role of desorption kinetics in the rhamnolipid-enhanced biodegradation of polycyclic aromatic hydrocarbons.
Congiu, E; Ortega-Calvo, JJ, 2014
)
0.64
" While the insignificant differences in PHE dissipation might be attributed to its higher solubility and availability under flooded condition that concealed the differences in improvement of bioavailability for microorganisms between rhizosphere and non-rhizosphere, and between both soils and both rice cultivars."( Dissipation of phenanthrene and pyrene at the aerobic-anaerobic soil interface: differentiation induced by the rhizosphere of PAH-tolerant and PAH-sensitive rice (Oryza sativa L.) cultivars.
He, Y; Li, X; Lin, J; Wu, J; Xia, W; Xu, J, 2015
)
0.7
"The degrading genes of hydrophobic organic compounds (HOCs) serve as indicators of in situ HOC degradation potential, and the existing forms and bioavailability of HOCs might influence the distribution of HOC-degrading genes in natural waters."( Response of PAH-degrading genes to PAH bioavailability in the overlying water, suspended sediment, and deposited sediment of the Yangtze River.
Dong, J; Huang, J; Lai, Y; Li, Z; Xia, N; Xia, X; Ye, W; Yuan, Y; Zhao, P; Zhu, B, 2015
)
0.42
"Carbon nanotubes (CNTs) may affect bioavailability and toxicity of organic contaminants due to their adsorption properties."( The influence of multiwalled carbon nanotubes on polycyclic aromatic hydrocarbon (PAH) bioavailability and toxicity to soil microbial communities in alfalfa rhizosphere.
Acosta-Martinez, V; Anderson, TA; Cañas-Carrell, JE; Payton, P; Shrestha, B, 2015
)
0.42
" Association of strongly hydrophobic contaminants (HOCs) with DOM leads to decreased toxicity and bioavailability, but bioavailability of DOM-sorbed HOCs is difficult to measure."( Application of isotope dilution method for measuring bioavailability of organic contaminants sorbed to dissolved organic matter (DOM).
Delgado-Moreno, L; Gan, J; Wu, L, 2015
)
0.42
" It is proposed that the bacterial-produced EPS was a key factor to mediate bacterial attachment to other surfaces and develop biofilms, thereby increasing the bioavailability of poorly soluble PAH for enhanced biodegradation."( Extracellular polymeric substances govern the development of biofilm and mass transfer of polycyclic aromatic hydrocarbons for improved biodegradation.
Jiang, X; Wang, F; Zeng, J; Zhang, Y; Zhao, Q; Zhu, X, 2015
)
0.42
" triqueter on bioavailability of PYR and Pb suggested that organic acids enhanced the bioavailability of PYR and Pb in wetland soil, and the bioavailability effects of organic acids generally followed the same order as that of desorption effects."( Identification of Scirpus triqueter root exudates and the effects of organic acids on desorption and bioavailability of pyrene and lead in co-contaminated wetland soils.
Chen, X; He, C; Hou, Y; Liang, X; Liu, X; Tao, K; Zhang, X, 2015
)
0.63
"We investigated the effects of different bioavailability scenarios on the rhamnolipid-enhanced biodegradation of pyrene by the representative polycyclic aromatic hydrocarbon degrader Mycobacterium gilvum VM552."( Dual partitioning and attachment effects of rhamnolipid on pyrene biodegradation under bioavailability restrictions.
Congiu, E; Ortega-Calvo, JJ; Parsons, JR, 2015
)
0.87
" However, the bioavailability of hydrophobic organic compounds (HOCs) associated with SPS is not well understood."( Bioavailability of Pyrene Associated with Suspended Sediment of Different Grain Sizes to Daphnia magna as Investigated by Passive Dosing Devices.
Dong, J; Li, H; Xia, X; Zhang, X; Zhu, B, 2015
)
0.75
"In this study, column leaching experiments were used to evaluate the leachability, distribution and bioavailability of phenanthrene and pyrene by root exudates from contaminated mangrove sediments."( Effects of root exudates on the leachability, distribution, and bioavailability of phenanthrene and pyrene from mangrove sediments.
Dai, M; Jia, H; Li, J; Liu, J; Lu, H; Yan, C, 2016
)
0.85
"Hydrophobic organic compounds (HOCs) tend to associate with suspended sediment (SPS) in aquatic environments; the composition and grain size of SPS will affect the bioavailability of SPS-associated HOCs."( Importance of suspended sediment (SPS) composition and grain size in the bioavailability of SPS-associated pyrene to Daphnia magna.
Bao, Y; Li, H; Xia, X; Zhai, Y; Zhang, X; Zhou, D, 2016
)
0.65
" The positive impact of surfactants on pyrene remediation could possibly be because of their capacities to increase its bioavailability in soil."( Surfactant enhanced pyrene degradation in the rhizosphere of tall fescue (Festuca arundinacea).
Cheema, SA; Chen, Y; Farooq, M; Khan, MI; Shen, C; Tang, X, 2016
)
1.03
"The objectives of this study were to investigate the mutual effect of the PAHs fluorene and pyrene on their respective biodegradation and dissipation processes in an agricultural soil, and to determine the effect of hydroxypropyl-β-cyclodextrin (HPBCD), used to increase the bioavailability of PAHs, on such processes."( Natural attenuation of fluorene and pyrene in contaminated soils and assisted with hydroxypropyl-β-cyclodextrin. Effect of co-contamination.
Madrid, F; Morillo, E; Rubio-Bellido, M; Tejada, M; Villaverde, J, 2016
)
0.93
" crispus) on bioavailability and biodegradation activity of pyrene in aged and unaged sediments, model calculation based on experimental results was carried out."( Effect of Potamogeton crispus L. on bioavailability and biodegradation activity of pyrene in aged and unaged sediments.
Chi, J; Meng, F, 2017
)
0.92
" The addition of PGPB efficiently decreased bioaccessible fractions of pyrene and increased the bioavailability of Ni in both rhizospheric and non-rhizospheric soil."( Phytoremediation effect of Scirpus triqueter inoculated plant-growth-promoting bacteria (PGPB) on different fractions of pyrene and Ni in co-contaminated soils.
Cao, L; Chen, X; Hu, X; Liu, X; Zhang, X, 2017
)
0.9
" Sorption of organic chemicals by microplastics may affect the distribution and bioavailability of the chemicals."( Comparative evaluation of sorption kinetics and isotherms of pyrene onto microplastics.
Wang, J; Wang, W, 2018
)
0.72
" Sediment organic matter (OM) and clay play an important role in the biodegradation and bioavailability of PAHs."( The role of organic matter and clay content in sediments for bioavailability of pyrene.
Dalmacija, B; Grgić, M; Krčmar, D; Maletić, S; Rončević, S; Spasojević, J; Varga, N, 2018
)
0.71
"Oral bioavailability of a drug molecule requires its effective delivery to the target site."( Drug Partitioning in Micellar Media and Its Implications in Rational Drug Design: Insights with Streptomycin.
Judy, E; Kishore, N; Pagariya, D, 2018
)
0.48
" A direct plant exposure assay in combination with an organic solvent extraction experiment was carried out in this study to investigate the bioavailability of polycyclic aromatic hydrocarbons (PAHs) with the application of pine needle biochars pyrolyzed under different temperatures (100, 300, 400, and 700 °C; referred as P100-P700 accordingly)."( Reduced bioavailability and plant uptake of polycyclic aromatic hydrocarbons from soil slurry amended with biochars pyrolyzed under various temperatures.
Chen, B; Wang, Y; Zhang, Y; Zhu, X, 2018
)
0.48
" However, it is still unclear how sludge conditioning treatments impact the bioavailability of polycyclic aromatic hydrocarbons (PAHs) in sewage sludge that potentially influences the biodegradation of PAHs during the composting of dewatered sludge cake."( Impact of sludge conditioning treatment on the bioavailability of pyrene in sewage sludge.
Jiang, S; Lu, Y; Xiao, Y; Zheng, G; Zhou, L; Zhou, W, 2018
)
0.72
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" In this context, a leaching procedure and pot experiment (60-d) were performed on migration and transformation of PAH at the sediment, and toxicity and their bioavailability in plant affected by the presence of Kandelia obovate-derived biochar in Southeast China."( Evaluation and characterization of biochar on the biogeochemical behavior of polycyclic aromatic hydrocarbons in mangrove wetlands.
Jia, H; Peng, W; Tang, D; Wang, H; Wu, Y; Ye, J; Zhang, M, 2023
)
0.91
" In this study, we integrated bioavailability measurements into persistence testing of pollutants in soil to show that it is the key to have a more realistic environmental risk assessment (ERA)."( Integrating bioavailability measurements in persistence testing of partially biodegradable organic chemicals in soil.
Fernández-López, C; Hennecke, D; Ortega-Calvo, JJ; Posada-Baquero, R, 2024
)
1.44

Dosage Studied

The ability to effectively monitor these endpoints in short-term and repeated dosing schedules was investigated with the carcinogen/noncarcinogen pair benzo(a)pyrene (BP) and pyrene (Pyr) The addition of a moderate dosage of pyrene lessened heavy metal toxicity to plants.

ExcerptRelevanceReference
"A biologically based toxicokinetic model was developed to stimulate the metabolic disposition of pyrene in trout with an average body weight of 450 g and dosed with a single bolus injection of the chemical (10 mg/kg)."( A biologically based toxicokinetic model for pyrene in rainbow trout.
Abedini, S; Kennedy, CJ; Law, FC, 1991
)
0.76
" Besides, dependence of theophylline elimination rate constant on the time of chrysene dosing was also shown."( The effect of chrysene and some polycyclic aromatic hydrocarbons on the elimination of theophylline in rats.
Brandys, J; Piekoszewski, W, 1985
)
0.27
" Dose-response curves based on chemical concentration and light intensity revealed that the order of phytotoxic strength was fluoranthene > pyrene > naphthalene."( Photoinduced toxicity of three polycyclic aromatic hydrocarbons (fluoranthene, pyrene, and naphthalene) to the duckweed Lemna gibba L. G-3.
Dixon, DG; Greenberg, BM; Huang, XD; McConkey, BJ; Ren, L, 1994
)
0.72
"Groups of 12 male Wistar rats, of about 400 g body weight, were dosed with 2, 6, or 15 mg/kg of 14C-labeled pyrene, dissolved in acetone, applied to 4 cm2 of a shaved area of the mid back."( Percutaneous uptake, distribution, and excretion of pyrene in rats.
Endrenyi, L; Law, FC; Withey, JR, 1993
)
0.75
" Furthermore, the time course of 1-OHP excretion in either bile or urine following intravenous dosing resembled that observed after oral administration."( Urinary and biliary excretion kinetics of 1-hydroxypyrene following intravenous and oral administration of pyrene in rats.
Bouchard, M; Viau, C, 1998
)
0.55
" Groups of male Wistar rats were dosed with pyrene and with mixture of pyrene and fluoranthene, pyrene and benz[a]anthracene, or pyrene, fluoranthene, and benz[a]anthracene at 20 mg/kg by intravenous or oral routes."( Effect of polycyclic aromatic hydrocarbons on the elimination kinetics of pyrene and the urinary excretion profile of 1-hydroxypyrene in the rat.
Lipniak-Gawlik, M, 1998
)
0.79
" Bioaccumulation experiments were performed with Lumbriculus variegatus and Diporeia species exposed in seven sediments dosed with 2,4,5,2',4',5'-hexachlorobiphenyl (HCBP) and benzo[a]pyrene (BaP) or pyrene (PY) and 3,4,3',4'-tetrachlorobiphenyl (TCBP)."( The contrasting roles of sedimentary plant-derived carbon and black carbon on sediment-spiked hydrophobic organic contaminant bioavailability to Diporeia species and Lumbriculus variegatus.
Gossiaux, DC; Gunnarsson, J; Kukkonen, JV; Landrum, PF; Mitra, S; Weston, D, 2005
)
0.52
" Dose-response curves for growth inhibition were determined and four concentrations eliciting from "no effect" up to a severe growth inhibition were chosen for further investigation to detect alterations at gene expression level by Real-Time PCR."( Gene regulation in the marine diatom Thalassiosira pseudonana upon exposure to polycyclic aromatic hydrocarbons (PAHs).
Bopp, SK; Lettieri, T, 2007
)
0.34
" Reaction kinetics of pyrene removal were dominated by the iron dosage and approximated by a pseudo-first-order model."( Remediation of pyrene-contaminated soil by synthesized nanoscale zero-valent iron particles.
Chang, MC; Kang, HY, 2009
)
1.02
" Induction kinetics were calculated using a logistic-like model and approximate dose-response curves were designed."( EROD activity in peripheral blood lymphocytes and 1-hydroxypyrene in urine and milk as biomarkers of PAH exposure in dairy ruminants.
Chahin, A; Dziurla, MA; Guiavarc'h, YP; Jondreville, C; Rychen, G; Yen, FT, 2011
)
0.61
" The ability to effectively monitor these endpoints in short-term and repeated dosing schedules was investigated with the carcinogen/noncarcinogen pair benzo(a)pyrene (BP) and pyrene (Pyr)."( In vivo flow cytometric Pig-a and micronucleus assays: highly sensitive discrimination of the carcinogen/noncarcinogen pair benzo(a)pyrene and pyrene using acute and repeated-dose designs.
Avlasevich, SL; Bell, S; Bemis, JC; Bryce, SM; Custer, LL; Dertinger, SD; Gleason, C; MacGregor, JT; Mereness, J; Phonethepswath, S; Torous, DK; Weller, P, 2012
)
0.78
" The addition of a moderate dosage of pyrene (100 mg/kg) lessened heavy metal toxicity to plants, resulting in enhanced plant growth and increased metal accumulation in plant tissues, thus improving heavy metal removal by plants."( Interaction of heavy metals and pyrene on their fates in soil and tall fescue (Festuca arundinacea).
Lu, M; Wang, JX; Wu, XJ; Xu, YX; Zhang, M; Zhang, ZZ, 2014
)
0.96
" The higher remediation efficiency of low dosage SDBS-Tween 80 mixed surfactants thus advanced the technology of surfactant-enhanced plant-microbe associated bioremediation."( Enhancing plant-microbe associated bioremediation of phenanthrene and pyrene contaminated soil by SDBS-Tween 80 mixed surfactants.
Ni, H; Zhou, W; Zhu, L, 2014
)
0.64
" To fill this gap, this study investigated the effect of predation on the bioaccumulation of polycyclic aromatic hydrocarbons (PAHs), one type of HOC, in low-to-high aquatic trophic levels under constant freely dissolved PAH concentrations (1, 5, or 10 μg L(-1)) maintained by passive dosing systems."( How does predation affect the bioaccumulation of hydrophobic organic compounds in aquatic organisms?
Li, H; Wang, H; Xia, X; Yang, Z; Zhang, X, 2015
)
0.42
" In this work, the influence of SPS grain size on the bioavailability of SPS-associated pyrene to Daphnia magna was studied using a passive dosing device, which maintained a constant freely dissolved pyrene concentration (Cfree) in the exposure systems."( Bioavailability of Pyrene Associated with Suspended Sediment of Different Grain Sizes to Daphnia magna as Investigated by Passive Dosing Devices.
Dong, J; Li, H; Xia, X; Zhang, X; Zhu, B, 2015
)
0.97
" In this work, passive dosing devices were made to control the freely dissolved concentration of pyrene, a typical HOC, in the exposure systems."( Importance of suspended sediment (SPS) composition and grain size in the bioavailability of SPS-associated pyrene to Daphnia magna.
Bao, Y; Li, H; Xia, X; Zhai, Y; Zhang, X; Zhou, D, 2016
)
0.87
" Eight-week old male rats were orally dosed with Pyr at 500, 1000, and 2000 mg/kg or ethylnitrosourea (ENU) at 10 and 40 mg/kg as a positive control."( Pyrene did not induce gene mutation in red blood cell Pig-a assay and PIGRET assay in rats.
Harada, Y; Hashizume, T; Matsumoto, A; Sakai, Y; Yoshida, I, 2016
)
1.88
"Giving patients right dosage is an essential concept of precision medicine."( Intercalating pyrene with polypeptide as a novel self-assembly nano-carrier for colon cancer suppression in vitro and in vivo.
Cho, EC; Huang, JH; Lee, GY; Lee, KC; Lo, PY; Zheng, JH, 2020
)
0.92
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
fluorescent probeA role played by a fluorescent molecular entity used to study the microscopic environment by fluorescence spectroscopy.
persistent organic pollutantAny environmental contaminant that is resistant to environmental degradation through photolytic, biological or chemical processes. Such substances can have significant impact on health and the environment, as they persist in the environment, bioaccumulate in animal tissue and so biomagnify in food chains.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
ortho- and peri-fused polycyclic arene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (57)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID886; AID893
RAR-related orphan receptor gammaMus musculus (house mouse)Potency11.39240.006038.004119,952.5996AID1159521
GALC proteinHomo sapiens (human)Potency1.584928.183828.183828.1838AID1159614
GLI family zinc finger 3Homo sapiens (human)Potency18.05570.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency27.64750.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency12.58930.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency60.58050.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency23.62360.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency64.06390.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency7.44100.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency9.12680.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency47.94430.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency48.09540.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency40.21920.001530.607315,848.9004AID1224819; AID1224820; AID1224841; AID1224842; AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency28.61380.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency25.50430.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency39.49670.000229.305416,493.5996AID1259244; AID1259383; AID743069; AID743075; AID743078; AID743079; AID743080
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency48.35910.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency50.11870.001019.414170.9645AID588537
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency57.58640.023723.228263.5986AID743222
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency40.42160.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency7.18810.001628.015177.1139AID1224843
activating transcription factor 6Homo sapiens (human)Potency12.89200.143427.612159.8106AID1159516
Histone H2A.xCricetulus griseus (Chinese hamster)Potency118.46700.039147.5451146.8240AID1224845
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency12.58930.001815.663839.8107AID894
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.63100.010039.53711,122.0200AID588547
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency14.12540.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency28.61630.000323.4451159.6830AID743065
heat shock protein beta-1Homo sapiens (human)Potency22.92560.042027.378961.6448AID743210
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency32.97520.000627.21521,122.0200AID651741; AID743202
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency10.00000.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency7.94330.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency57.09700.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency80.65170.002319.595674.0614AID651631
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency57.09700.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A1Homo sapiens (human)IC50 (µMol)0.04100.00791.24789.9000AID1452981; AID311073
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)0.00700.00011.774010.0000AID311074
Polypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)IC50 (µMol)100.00000.51001.64373.1200AID1588066
Cytochrome P450 1B1Homo sapiens (human)IC50 (µMol)0.00200.00130.86969.9000AID1452980; AID311072
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (230)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1A1Homo sapiens (human)
response to hypoxiaCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
lipid hydroxylationCytochrome P450 1A1Homo sapiens (human)
fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid metabolic processCytochrome P450 1A1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A1Homo sapiens (human)
amine metabolic processCytochrome P450 1A1Homo sapiens (human)
response to nematodeCytochrome P450 1A1Homo sapiens (human)
response to herbicideCytochrome P450 1A1Homo sapiens (human)
ethylene metabolic processCytochrome P450 1A1Homo sapiens (human)
coumarin metabolic processCytochrome P450 1A1Homo sapiens (human)
flavonoid metabolic processCytochrome P450 1A1Homo sapiens (human)
response to iron(III) ionCytochrome P450 1A1Homo sapiens (human)
insecticide metabolic processCytochrome P450 1A1Homo sapiens (human)
dibenzo-p-dioxin catabolic processCytochrome P450 1A1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
response to foodCytochrome P450 1A1Homo sapiens (human)
response to lipopolysaccharideCytochrome P450 1A1Homo sapiens (human)
response to vitamin ACytochrome P450 1A1Homo sapiens (human)
response to immobilization stressCytochrome P450 1A1Homo sapiens (human)
vitamin D metabolic processCytochrome P450 1A1Homo sapiens (human)
retinol metabolic processCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
9-cis-retinoic acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
camera-type eye developmentCytochrome P450 1A1Homo sapiens (human)
nitric oxide metabolic processCytochrome P450 1A1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1A1Homo sapiens (human)
digestive tract developmentCytochrome P450 1A1Homo sapiens (human)
tissue remodelingCytochrome P450 1A1Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A1Homo sapiens (human)
response to hyperoxiaCytochrome P450 1A1Homo sapiens (human)
maternal process involved in parturitionCytochrome P450 1A1Homo sapiens (human)
hepatocyte differentiationCytochrome P450 1A1Homo sapiens (human)
cellular response to copper ionCytochrome P450 1A1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleCytochrome P450 1A1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1A1Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
protein O-linked glycosylationPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
O-glycan processingPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
protein O-linked glycosylation via serinePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
protein O-linked glycosylation via threoninePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
protein maturationPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1B1Homo sapiens (human)
angiogenesisCytochrome P450 1B1Homo sapiens (human)
trabecular meshwork developmentCytochrome P450 1B1Homo sapiens (human)
DNA modificationCytochrome P450 1B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1B1Homo sapiens (human)
nitric oxide biosynthetic processCytochrome P450 1B1Homo sapiens (human)
cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to nutrientCytochrome P450 1B1Homo sapiens (human)
steroid metabolic processCytochrome P450 1B1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell population proliferationCytochrome P450 1B1Homo sapiens (human)
male gonad developmentCytochrome P450 1B1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressCytochrome P450 1B1Homo sapiens (human)
toxin metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionCytochrome P450 1B1Homo sapiens (human)
positive regulation of smooth muscle cell migrationCytochrome P450 1B1Homo sapiens (human)
sterol metabolic processCytochrome P450 1B1Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 1B1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
collagen fibril organizationCytochrome P450 1B1Homo sapiens (human)
adrenal gland developmentCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell migrationCytochrome P450 1B1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityCytochrome P450 1B1Homo sapiens (human)
response to follicle-stimulating hormoneCytochrome P450 1B1Homo sapiens (human)
response to estradiolCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinCytochrome P450 1B1Homo sapiens (human)
benzene-containing compound metabolic processCytochrome P450 1B1Homo sapiens (human)
retinol metabolic processCytochrome P450 1B1Homo sapiens (human)
retinal metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of apoptotic processCytochrome P450 1B1Homo sapiens (human)
blood vessel endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
estrous cycleCytochrome P450 1B1Homo sapiens (human)
positive regulation of translationCytochrome P450 1B1Homo sapiens (human)
positive regulation of angiogenesisCytochrome P450 1B1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCytochrome P450 1B1Homo sapiens (human)
membrane lipid catabolic processCytochrome P450 1B1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1B1Homo sapiens (human)
blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
retinal blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
ganglion developmentCytochrome P450 1B1Homo sapiens (human)
cellular response to hydrogen peroxideCytochrome P450 1B1Homo sapiens (human)
cellular response to cAMPCytochrome P450 1B1Homo sapiens (human)
cellular response to tumor necrosis factorCytochrome P450 1B1Homo sapiens (human)
cellular response to luteinizing hormone stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to cortisol stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to progesterone stimulusCytochrome P450 1B1Homo sapiens (human)
response to dexamethasoneCytochrome P450 1B1Homo sapiens (human)
endothelial cell-cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to indole-3-methanolCytochrome P450 1B1Homo sapiens (human)
cellular response to toxic substanceCytochrome P450 1B1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1B1Homo sapiens (human)
regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of DNA biosynthetic processCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (59)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
iron ion bindingCytochrome P450 1A1Homo sapiens (human)
protein bindingCytochrome P450 1A1Homo sapiens (human)
arachidonic acid monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activity, acting on diphenols and related substances as donorsCytochrome P450 1A1Homo sapiens (human)
flavonoid 3'-monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxygen bindingCytochrome P450 1A1Homo sapiens (human)
enzyme bindingCytochrome P450 1A1Homo sapiens (human)
heme bindingCytochrome P450 1A1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 1A1Homo sapiens (human)
demethylase activityCytochrome P450 1A1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 1A1Homo sapiens (human)
aromatase activityCytochrome P450 1A1Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
polypeptide N-acetylgalactosaminyltransferase activityPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
protein bindingPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
manganese ion bindingPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
carbohydrate bindingPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
monooxygenase activityCytochrome P450 1B1Homo sapiens (human)
iron ion bindingCytochrome P450 1B1Homo sapiens (human)
protein bindingCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
heme bindingCytochrome P450 1B1Homo sapiens (human)
aromatase activityCytochrome P450 1B1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1B1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
mitochondrial inner membraneCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
Golgi apparatusPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
Golgi membranePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
extracellular regionPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
endoplasmic reticulum membranePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
Golgi apparatusPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
Golgi stackPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
membranePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
Golgi cisterna membranePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
perinuclear region of cytoplasmPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
Golgi apparatusPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
mitochondrionCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1B1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (51)

Assay IDTitleYearJournalArticle
AID288185Permeability coefficient through artificial membrane in presence of stirred water layer2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID603957Octanol-water partition coefficient, log P of the compound2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
QSPR modeling of octanol/water partition coefficient for vitamins by optimal descriptors calculated with SMILES.
AID1611221Aqueous solubility of compound in phosphate buffered saline at pH 7.4 incubated for 2 hrs by turbidimetric analysis2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID1452980Inhibition of human CYP1B1 expressed in Escherichia coli DH5alpha coexpressing human NADPH P450 reductase using 7-ethoxyresorufin as substrate in presence of NADPH by fluorimetric analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID1588066Inhibition of catalytic activity of human recombinant FLAG-tagged ppGalNAcT2 expressed in HEK293T cells and using 5-FAM labelled-EA2 peptide as substrate incubated for 30 mins by HPLC-based enzyme assay2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Inhibition of polypeptide N-acetyl-α-galactosaminyltransferases is an underlying mechanism of dietary polyphenols preventing colorectal tumorigenesis.
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID311073Inhibition of CYP1A12007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.
AID1588084Inhibition of ppGalNAcT2 in human HT-29 cells assessed as reduction in O-GalNAc glycans by measuring PNA lectin signal on cell surface at 40 uM incubated for 48 hrs by DAPI staining based immunofluorescence method2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Inhibition of polypeptide N-acetyl-α-galactosaminyltransferases is an underlying mechanism of dietary polyphenols preventing colorectal tumorigenesis.
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1160935Partition coefficient, log D of the compound at pH 7.42014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
AID160321Competition for [3H]benzo[a]pyrene-binding site of polycyclic aromatic hydrocarbon binding protein (PBP) from mouse liver1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Voronoi binding site model of a polycyclic aromatic hydrocarbon binding protein.
AID311074Inhibition of CYP1A22007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.
AID288191Membrane retention in permeability experiment with artificial membrane2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID311072Inhibition of CYP1B12007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.
AID1452985Selectivity index, ratio of IC50 for human CYP1A1 expressed in Escherichia coli DH5alpha coexpressing human NADPH P450 reductase to IC50 for human CYP1B1 expressed in Escherichia coli DH5alpha coexpressing human NADPH P450 reductase2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID1452981Inhibition of human CYP1A1 expressed in Escherichia coli DH5alpha coexpressing human NADPH P450 reductase using 7-ethoxyresorufin as substrate in presence of NADPH by fluorimetric analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,103)

TimeframeStudies, This Drug (%)All Drugs %
pre-199074 (3.52)18.7374
1990's174 (8.27)18.2507
2000's665 (31.62)29.6817
2010's1006 (47.84)24.3611
2020's184 (8.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 70.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index70.58 (24.57)
Research Supply Index7.68 (2.92)
Research Growth Index5.13 (4.65)
Search Engine Demand Index124.81 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (70.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.14%)5.53%
Reviews23 (1.06%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other2,137 (98.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]